Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,859,196
  • Shares Outstanding, K 192,114
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 596 M
  • EBITDA $ 685 M
  • 60-Month Beta 0.26
  • Price/Sales 3.68
  • Price/Cash Flow 21.64
  • Price/Book 1.95

Options Overview Details

View History
  • Implied Volatility 47.65% (+7.89%)
  • Historical Volatility 23.17%
  • IV Percentile 92%
  • IV Rank 72.48%
  • IV High 55.63% on 04/10/25
  • IV Low 26.64% on 03/24/25
  • Expected Move (DTE 18) 5.08 (8.23%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 6,697
  • Volume Avg (30-Day) 1,651
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 36,552
  • Open Int (30-Day) 32,296
  • Expected Range 56.65 to 66.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.97
  • Number of Estimates 7
  • High Estimate 1.20
  • Low Estimate 0.57
  • Prior Year 0.98
  • Growth Rate Est. (year over year) -1.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.28 +11.67%
on 01/30/26
66.28 -6.86%
on 02/24/26
+4.88 (+8.58%)
since 01/27/26
3-Month
50.90 +21.28%
on 12/15/25
66.28 -6.86%
on 02/24/26
+6.21 (+11.19%)
since 11/26/25
52-Week
50.76 +21.61%
on 11/07/25
73.51 -16.03%
on 03/07/25
-7.39 (-10.69%)
since 02/27/25

Most Recent Stories

More News
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study

BMRN : 61.73 (+1.01%)
BioMarin to Participate in Four Upcoming Investor Conferences in March

SAN RAFAEL, Calif. , Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

BMRN : 61.73 (+1.01%)
BioMarin: Q4 Earnings Snapshot

BioMarin: Q4 Earnings Snapshot

BMRN : 61.73 (+1.01%)
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BMRN : 61.73 (+1.01%)
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO ®

BMRN : 61.73 (+1.01%)
BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BMRN : 61.73 (+1.01%)
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

SAN RAFAEL, Calif. , Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

BMRN : 61.73 (+1.01%)
BioMarin Announces Closing of Private Offering of Senior Notes

SAN RAFAEL, Calif. , Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500%...

BMRN : 61.73 (+1.01%)
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500%...

BMRN : 61.73 (+1.01%)
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850...

BMRN : 61.73 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 65.73
2nd Resistance Point 64.48
1st Resistance Point 63.10
Last Price 61.73
1st Support Level 60.47
2nd Support Level 59.22
3rd Support Level 57.84

See More

52-Week High 73.51
Fibonacci 61.8% 64.82
Fibonacci 50% 62.14
Last Price 61.73
Fibonacci 38.2% 59.45
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar